Global Neutropenia Treatment Market 2017-2021
About Neutropenia Treatment
Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms. Decrease in the neutrophil count in blood makes a patient susceptible to infections and may even prove fatal. Therefore, the condition requires immediate prophylaxis.
Technavio’s analysts forecast the global neutropenia treatment market to grow at a CAGR of 4.45% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global neutropenia treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of neutropenia drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Neutropenia Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global neutropenia drugs market: Amgen, Novartis, and Teva Pharmaceutical
Other Prominent Vendors in the market are: Hospira and Pfizer
Commenting on the report, an analyst from Technavio’s team said: “The global neutropenia treatment market has been primarily dominated by the use of biologics and biosimilars for its prevention and cure. However, with the advances in pharmaceutical science and technology, vendors have gained a better understanding of the etiology and epidemiology of disease, thereby paving the path for development of novel therapeutics. Similarly, innovation of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals, with immune-boosting effects, is likely to revolutionize the therapeutic regimen for neutropenia.”
According to the report, biologics are being used in neutropenia therapeutics from a long period. Amgen's product NEUPOGEN, received its FDA approval in April 1998 and has been used extensively in the treatment of neutropenia, driving the growth of the global neutropenia market growth. In 1991, Amgen's NEUPOGEN was approved for use in cancer patients and in 1994, it was approved for use in bone marrow transplant. In both the cases, NEUPOGEN, was known to reduce the duration and associated-complications of neutropenia. NEUPOGEN is a biological product, having filgrastim as its main API (active pharmaceutical ingredient). The presence of such drugs with multiple indications helps drive the market growth. In 2002, the US FDA approved a PEGylated (polyethylene glycol modified) form of G-CSF analog filgrastim, Neulasta. This drug is an advanced version of earlier blockbuster NEUPOGEN, and received wide acceptance in the market. This wide acceptance was primarily due to the added customer convenience Neulasta offered in terms of dosage. This drug should be administered as a single dose per chemotherapy cycle unlike NEUPOGEN, which has to be administered on a daily basis throughout the chemotherapy cycle. Neulasta decreased the burden of frequent dosing to a great extent, thereby attracting a large patient pool. In addition, in March 2015, the US FDA approved Neulasta Onpro kit, on-body injector of G-CSF, which makes the drug administration more convenient. Such instances result in an increased patient adherence, driving the market growth. The neutropenia treatment market is growing rapidly and offers commercial opportunities for many pharmaceutical firms. For instance, NEUPOGEN, despite losing its patent protection in 2013, generated a revenue of $1 billion in 2013.
Further, the report states that the most common causative agents of neutropenia such as E.coli, Klebsiella spp., and P. aeruginosa pose a serious challenge for the management of neutropenia worldwide. In such cases, the traditional therapeutic regimen including the use of oral therapy, ceftazidime, cefepime, piperacillin-tazobactam, and carbapenems serve to be ineffective in treating the neutropenia-associated complications. Bloodstream infections (BSI) are the most common complications that frequently occur in the neutropenic patients, and most of these infections are caused by Gram-negative bacteria and are associated with high mortality rate. These infections cause a rise in body temperature above 100°F, which is termed as neutropenic fever. To treat this fever, various broad-spectrum antibiotics are used, which are effective against the most common causative agents. However, due to the rise in prevalence of MDR in these agents, a new de-escalation approach has been introduced to treat patients who are at a greater risk of infection due to MDR bacterial strain. The onset of this new de-escalation approach starts with the administration of antibiotic, which is effective against the most common resistant strain, and its frequency of dosing is decreased if no MDR bacteria is isolated.
Amgen, Novartis, Teva Pharmaceutical, Hospira and Pfizer
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook